<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Provectus Biopharmaceuticals, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=23050></link><description><![CDATA[Provectus Biopharmaceuticals, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 16 May 2026 06:54:54 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2014/08/740813719_20140819133353_1122948009.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.]]></title><link>https://www.newswire.co.kr/newsRead.php?no=762720</link><description><![CDATA[KNOXVILLE, Tenn.--(Business Wire/Korea Newswire)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) , a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it entered into a Memorandum of Understanding (“MOU”) with Sinopharm-China State Institute of Pharmaceutical Industry (“Sinopharm-CSIPI”), the leader among all pharmaceutical research in...]]></description><pubDate>Tue, 19 Aug 2014 13:40:00 +0900</pubDate></item><item><title><![CDATA[프로벡터스, 시노팜-중국 국영 제약산업 연구소 및 시노팜 A-씽크 제약과 양해각서 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=762721</link><description><![CDATA[녹스빌, 테네시--(Business Wire/뉴스와이어)--종양 및 피부질환 치료제의 임상 개발 단계인 바이오제약 회사 프로벡터스 바이오파마슈티컬스(Provectus Biopharmaceuticals, Inc., 이하 프로벡터스)(뉴욕증권거래소 MKT: PVCT)는 중국 최고의 제약 연구소인 시노팜-중국 국영 제약산업연구소(Sinopharm-China State Institute of Pharmaceutical Industry, 이하 시노팜-CSIPI)와 시노팜 그룹(Sinopharm Group) 산하 기업...]]></description><pubDate>Tue, 19 Aug 2014 13:40:00 +0900</pubDate></item></channel></rss>